Intuitive Surgical, Inc.

What they do

Intuitive designs, manufactures, and sells robotic-assisted surgical systems (da Vinci and Ion) and associated instruments, accessories, and services. The company also provides customer learning, support services, and a digital portfolio for actionable insights across the care continuum. It operates globally, with direct sales in many markets and distribution in others.

Revenue drivers

• Instruments and Accessories — Largest revenue stream, driven by procedure volume. Q2 2026 revenue was $1.73 billion, up 18% YoY, reflecting ~15% da Vinci and ~36% Ion procedure growth.
• Systems — Revenue from sales and leases of da Vinci and Ion systems. Q2 2026 revenue was $685 million, up from $575 million in Q2 2025, driven by higher lease installed base, higher ASPs, and increased placements.
• Services and Other — Includes installation, repair, maintenance, technical support, and system monitoring. Revenue grows with the installed base, which reached 11,710 da Vinci and 1,096 Ion systems as of June 30, 2026.

Recent performance

For Q2 2026, Intuitive reported revenue of $2.89 billion, up 19% YoY. GAAP net income was $818 million ($2.29 per diluted share), while non-GAAP net income was $1.00 billion ($2.80 per diluted share). The company placed 468 da Vinci systems (246 da Vinci 5) and 55 Ion systems. GAAP income from operations was $972 million, up from $743 million in Q2 2025.

Strategy

Management focuses on expanding the installed base and procedure adoption, particularly for da Vinci 5 and Ion. They are transitioning to direct sales in certain markets (e.g., Italy, Spain, Portugal) and investing in R&D and digital capabilities. They also emphasize clinical evidence, cost-effectiveness, and expanding access to minimally invasive care.

Risks

• Competition and adoption — Customers may choose alternatives like open surgery, laparoscopy, or competing robotic systems (e.g., domestic competitors in China), reducing demand.
• Macroeconomic and trade risks — Tariffs, inflation, and hospital capital spending cuts could impact demand and costs; Q2 2026 had a $28 million benefit from prior tariff refunds.
• Regulatory and clearance delays — Delays in FDA or international clearances (e.g., da Vinci 5 in new markets) could slow launches and growth.
• Supply chain and manufacturing — Reliance on sole- and single-sourced suppliers and manufacturing in Mexico (subject to tariffs) could disrupt supply or increase costs.

Outlook

Management expects continued procedure growth, driven by da Vinci and Ion, and increasing adoption of da Vinci 5. They anticipate a phased international launch of da Vinci 5 and continued transition to direct sales in some regions. Forward-looking statements note potential impacts from tariffs, competition, and regulatory changes, but no specific financial guidance is provided.